SALT LAKE CITY, Oct. 18, 2016 -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that more than 40 of its employees are volunteering to support Project BioEYES, which is a science, technology, engineering and math (STEM) education program designed to teach K-12 students about cell biology, genetics and careers in science. Employees will spend a day in the classroom helping students formulate scientific hypotheses, design experiments and collect data, as well as sharing their own experiences from working in the life sciences.
“The BioEYES program is an ideal opportunity for us to support STEM education in Utah. These programs benefit us all by inspiring students to become tomorrow's innovators and pursue careers in the sciences,” said Mark C. Capone, president and CEO. “Myriad has long been one of the top STEM employers in the state, and we believe that volunteering for programs like this benefits our employees, our communities and our Company.”
Employees attended an orientation session to prepare for their work in the classroom. They learned how to help the students conduct experiments and understand what is entailed in research and the scientific method.
“We are delighted to have the support of Myriad and its employees in educating students about science,” said Judith Neugebauer, Ph.D., BioEYES Utah Program Manager. “These volunteers will help us offer the students opportunities to explore the life sciences by conducting real experiments and sharing their passion for science. Together, we will introduce children to the thrill of scientific discovery.”
For more information, follow us on Twitter via @bioeyes and @MyriadGenetics.
About BioEYES
BioEYES is a K-12 science education program, sponsored by the Department of Pediatrics at the University of Utah that provides active, inquiry-based learning opportunities through the use of live zebrafish. During their program week, students explore both adult and embryonic zebrafish and, by week’s end, they examine the beating heart and blood cells of the zebrafish larvae. The program is designed to incorporate teacher empowerment and provides professional development seminars and a co-teaching experience with trained science consultants, called outreach educators. BioEYES is located at the University of Pennsylvania in Philadelphia, PA; the Carnegie Institution for Science in Baltimore, MD; Monash University in Melbourne, Australia; and the University of Utah in Salt Lake City, UT. Since its inception it has reached over 100,000 students.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra, Prolaris and GeneSight are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G
Media Contact: Ron Rogers (801) 584-3065 [email protected] Investor Contact: Scott Gleason (801) 584-1143 [email protected]


Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Instagram Outage Disrupts Thousands of U.S. Users
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 



